Skip to main content
SpringerLink
Log in

Pharmacological Management of ADHD

  • Chapter
  • First Online:
A Clinician’s Guide to ADHD

  • 3776 Accesses

Abstract

Medications should only be used when symptoms are pervasive across settings (e.g., school and home), and are causing significant impairment in academic, social or behavioral function, and after careful consideration of non-pharmacological approaches.

Warning

This document does not include all of the medications, safety, and efficacy information available. It is provided as a professional courtesy to provide pertinent data that will assist you in forming your own conclusions and making your own decisions. Please consult each Product Monograph of each product for detailed prescribing information.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

General References and Related Reading

  • Adler LA, Spencer TJ, Milton DR et al (2005) Long term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit hyperactivity disorder: an interim analysis. J Clin Psychiatry 66(3):294–299

    Article  PubMed  CAS  Google Scholar 

  • Adler LA, Spencer TJ, Faraone SV et al (2006) Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 67(3):415–420

    Google Scholar 

  • Baranski JV, Pigeau R, Dinich P et al (2004) Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 19(5):323–332

    Article  PubMed  CAS  Google Scholar 

  • Biederman J, Balderssarini RJ, Wright V et al (1989) A double-bind placebo controlled study of Desipramine in the treatment of attention deficit disorder: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777–784

    Article  PubMed  CAS  Google Scholar 

  • Biederman J, Melmed RD, Patel A et al (2008) A randomized, double-blind, placebo-controlled study of Guanfacine extended release in children and adolescents with attention-deficit hyperactivity disorder. Pediatrics 121(1):e73–e84

    Article  PubMed  Google Scholar 

  • CADDRA (2011) Canadian ADHD Practice Guidelines [online] In: Umesh J, Hechtman L et al., editors. www.caddra.ca

  • Childress AC, Berry SA (2012) Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents. Drugs 72(3):309–325

    Article  PubMed  CAS  Google Scholar 

  • Coghil D (2011) Pragmatic measures in paediatric psychopharmacology – are we getting it right? Eur Neuropsychopharmacol 21(8):571–583

    Article  Google Scholar 

  • Conners CK, Casat CD, Gualtieri CT et al (1996) Burpropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 35:1314–1321

    Article  PubMed  CAS  Google Scholar 

  • Connor DF (2005) Psychostimulants in attention deficit hyperactivity disorder. In: Gozal D, Molfese DL, editors. Attention deficit hyperactivity disorder: from genes to patients. New Jersey: Humana Press, pp. 487–527

    Google Scholar 

  • Connor DF, Findling RL, Kollins SH et al (2010) Effects of Guanfacine extended release, a nonscheduled alpha 1A-adrenoceptor agonist, on oppositional symptoms in children aged 6 to 12 years with a diagnosis of attention-deficit hyperactivity disorder and the presence of oppositional symptom. CNS Drugs 24(9):755–768

    PubMed  CAS  Google Scholar 

  • Daughton JM, Kratochvil CJ (2009) Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adoloesc Psychiatry 48(3):240–248

    Article  Google Scholar 

  • Davidson MA (2008) ADHD in adults: a review of the literature. J Atten Disord 11(6):628–641

    Article  PubMed  Google Scholar 

  • Dopheide JA, Pliszka SR (2009) Attention-deficit hyperactivity disorder: an update. Pharmacotherapy 29(6):656–679

    Article  PubMed  Google Scholar 

  • Findling RL (2008) Evolution of the treatment of attention-deficit hyperactivity disorder in children: a review. Clin Ther 30(5):942–957

    Article  PubMed  CAS  Google Scholar 

  • Garnock-Jones KP, Keating GM (2010) Spotlight on Atomoxetine in attention-deficit hyperactivity disorder in children and adolsecents. CNS Drugs 24(1):85–88

    Article  PubMed  Google Scholar 

  • Graham J, Coghill D (2008) Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 22(3):231–237

    Article  Google Scholar 

  • Greenhill LL, Biederman J, Boellner SW (2002) A randomized, double-blind, placebo-controlled study of Modafinil film-coated tablets in children and adolescents with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45(5):503–511

    Article  Google Scholar 

  • Greenhill L, Kollins S et al (2006) Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45(11):1284–93

    Google Scholar 

  • Horst WD, Preskorn SH (1998) Mechanisms of action and clinical characteristic of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237–254

    Article  PubMed  CAS  Google Scholar 

  • Huang YS, Tsai MH (2001) Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge. CNS Drugs 25(7):539–554, Erratum in: CNS Drugs. 2011 Nov. 1, 25(11): 932, Dosage error in article text

    Article  Google Scholar 

  • Humphreys C, Carcia-Bournissen F, Ito S, Koren G (2007) Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Physician 53(7):1153–1155

    PubMed  Google Scholar 

  • Kaplan G, Newcorn JH (2011) Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin N Am 58(1):99–120, xi

    Article  Google Scholar 

  • Kolar D (2008) Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 4(2):389–403

    PubMed  CAS  Google Scholar 

  • Kratochvil DJ, Newcorn JH, Arnold LE (2005) Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44(9):915–924

    Article  PubMed  Google Scholar 

  • Kratochvil CJ, Wilens TE, Grennhill LL et al (2006) Effects of long term Atomoxetine treatment for young children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45(8):919–927

    Article  PubMed  Google Scholar 

  • Levin FR, Evans SM, McDowell DM et al (2002) Bupropion treatment for cocaine abuse and adult attention-deficit hyperactivity disorder. J Addict Disord 21(2):1–16

    Article  Google Scholar 

  • Lin JS, Gervansoni D, Hou Y et al (2000) Effects of amphetamine and Modafinil on the sleep/wake cycle during experimental hypersomnia induces by sleep deprivation in the cat. J Sleep Res 9(1):89–96

    Article  PubMed  CAS  Google Scholar 

  • Meijer WM, Faber A, van den Ban E, Tobi H (2009) Current issues around the pharmacotherapy of ADHD in children and adults. Pharm World Sci 31(5):509–516, Epub 2009 Jun 27

    Article  PubMed  Google Scholar 

  • Michelson D, Faries DE, Wernicke J et al (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit hyperactivity disorder: a randomized, placebo controlled, dose–response study. Pediatrics 108(5):E83

    Article  PubMed  CAS  Google Scholar 

  • Michelson D, Kratochvil CJ, Heligenstein JH et al (2002) Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41(7):776–784

    Article  PubMed  Google Scholar 

  • Michelson D, Adler L, Spencer T et al (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53(2):112–120

    Article  PubMed  CAS  Google Scholar 

  • Murray DW (2010) Treatment of preschoolers with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 12(5):374–381

    Article  PubMed  CAS  Google Scholar 

  • Pliszka SR et al (2006) Texas Consensus Conference Panel on Pharmacotherapy of childhood attention deficit hyperactivity disorder. The Texas Childrens’ Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45(6):642–657

    Article  PubMed  Google Scholar 

  • Pliszka S (2007) AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(7):894–921

    Google Scholar 

  • Prince JB (2006) Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, Atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am 15(1):13–50

    Article  PubMed  Google Scholar 

  • Pringsheim T, Steeves T (2011) Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev (4):CD007900

    Google Scholar 

  • Rostain AL (2008) Attention-deficit hyperactivity disorder in adults: evidence-based recommendations for management. Postgrad Med 120(3):27–38

    Article  PubMed  Google Scholar 

  • Safety and side effect information in children, teens and adults (2011). http://www.strattera.com

  • Salle FR, McGough J, Wigel T et al (2009) Guanfacine extended release in children and adolescents with attention-deficit hyperactivity disorder: a placbo-controlled trial. J Am Acad Child Adolesc Psychiatry 48(2):155–165

    Article  Google Scholar 

  • Sallee FR, Eaton K (2010) Guanfacine extended-release for attention-deficit hyperactivity disorder (ADHD). Expert Opin Pharmacother 11(15):2549–2556

    Article  PubMed  CAS  Google Scholar 

  • Santosh PJ, Sattar S, Canagaratnam M (2011) Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs 25(9):737–763

    Article  PubMed  CAS  Google Scholar 

  • Schachar R, Ickowicz A, Crosbie J et al (2008) Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 18(1):11–24

    Article  PubMed  Google Scholar 

  • Slatkoff J, Greenfiled B (2006) Pharmacological treatment of attention-deficit hyperactivity disorder in adults. Expert Opin Investig Drugs 15(6):649–667

    Article  PubMed  CAS  Google Scholar 

  • Solkhah R, Wilens TE, Daly J et al (2005) Burpropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 15(5):777–786

    Article  Google Scholar 

  • Spencer TJ, Greenbaum M, Ginsger LD, Murphy WR (2009) Safety and effectiveness of co-administration of Guanfacine extended release and psychostimulants in children and adolescents with attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 19(5):501–510

    Article  PubMed  Google Scholar 

  • Swanson JM, Greenhill LL, Lopez FA et al (2006) Modafinil film-coated tablets in children and adolescents with attention – deficit hyperactivity disorder: results of a randomized, double-blind, placebo-controlled fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 67(1):137–147

    Article  PubMed  CAS  Google Scholar 

  • Turner DC, Clark L, Dowson J et al (2004) Modafinil improves cognition and response inhibition in adult attention-deficit hyperactivity disorder. Biol Psychiatry 55(10):1031–1040

    Article  PubMed  CAS  Google Scholar 

  • Vitiello B (2008) Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 17(2):459–474, xi

    Article  PubMed  Google Scholar 

  • Wang Y, Zheng Y, Du Y et al (2007) Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 41(3):222–30

    Google Scholar 

  • Wernicke JF, Kratochvil CJ (2002) Safety profile of Atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63(12):50–55

    PubMed  CAS  Google Scholar 

  • Wigal SB (2009) Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 23(1):21–31

    Article  PubMed  CAS  Google Scholar 

  • Wigal SB, Cahe S, Patel A, Steinberg-Epstein R (2010) Advances in the treatment of attention-deficit hyperactivity disorder: a guide for pediatric neurologists. Semin Pediatr Neurol 17(4):230–236

    Article  PubMed  Google Scholar 

  • Wilens TE (2006) Mechanism of action of agents used in attention-deficit hyperactivity disorder. J Clin Psychiatry 67(8):32–38

    PubMed  CAS  Google Scholar 

  • Wilens TE, Spencer TJ (2010) Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 122(5):97–109

    Article  PubMed  Google Scholar 

  • Wilens TE, Spencer TJ, Biederman J et al (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158(2):282–288

    Article  PubMed  CAS  Google Scholar 

  • Wilens TE, Spencer TJ, Biederman J (2002) Attention deficit/hyperactivity disorder across the life span. Ann Rev Med 53:113–131

    Google Scholar 

  • Wilens TE, Newcorn JJ, Kratochovil CJ et al (2006) Long term Atomoxetine treatment in adolescents with attention-deficit hyperactivity disorder. J Pediatr 146(1):112–119

    Article  Google Scholar 

  • Wolraich ML et al (2005) Attention-deficit hyperactivity disorder among adolescents: a review of the diagnosis, treatment and clinical implications. Pediatrics 115(6):1734–1746

    Article  PubMed  Google Scholar 

ADHD Guidelines Available on the Internet

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada

    Joseph Sadek

Authors
  1. Joseph Sadek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sadek, J. (2014). Pharmacological Management of ADHD. In: A Clinician’s Guide to ADHD. Springer, Cham. https://doi.org/10.1007/978-3-319-02359-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-02359-5_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-02358-8

  • Online ISBN: 978-3-319-02359-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation